The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2026 | The impact of donor type on transplant outcomes in myelofibrosis
Juan Carlos Hernández-Boluda, MD, PhD, Hospital Clínico Universitario Valencia, Valencia, Spain, discusses the impact of donor type on outcomes of patients with myelofibrosis (MF) receiving an allogeneic stem cell transplant, highlighting that HLA matching remains crucial in this disease to minimize graft failure or poor graft function. Dr Hernández-Boluda notes that the influence of donor and patient age on transplant outcomes remains an unresolved question. This interview took place at the 52nd Annual Meeting of the EBMT in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Actually this same question is trying to be solved in different diseases and probably the answer is not the same in each disease. In myelofibrosis we have a particular issue which is the graft failure or poor graft function and this is more specific to this disease and what we have seen in retrospective studies from the EBMT is that actually that HLA match is very important...
Actually this same question is trying to be solved in different diseases and probably the answer is not the same in each disease. In myelofibrosis we have a particular issue which is the graft failure or poor graft function and this is more specific to this disease and what we have seen in retrospective studies from the EBMT is that actually that HLA match is very important. So the results nowadays of sibling HLA match and unrelated donor matches are very similar, but they are superior to those of transplants from donors that are HLA mismatched, like haploidentical donors or unrelated mismatched donors. And this is probably a little bit different than in other diseases. So for us, it’s still HLA-matched.
And we don’t have an answer still of how the donor age influences a transplant. There are some hints that possibly the results of matched-related donors in the elderly population are much closer to the matched-related donors than when you are dealing with a younger patient, with a younger donor. But this is still not completely established. But I think it may also depend on the age, of the patient’s age and the donor age. So this is what I’m going to tell you, an unsolved question, but HLA-matches are important still in this disease.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
